Triumeq 50 mg/600 mg/300 mg film-coated tablets

DRUG3 trials

Sponsors

Stichting TRICALS Foundation, Fondazione Penta Ets, Instituto De Investigacion Marques De Valdecilla

Conditions

AMYOTROPHIC LATERAL SCLEROSISColonization by methicillin-resistant S. aureus and gut microbiota in users of pre-exposure prophylaxis (PrEP) and people living with HIV (PLHIV) with STIs.HIV-infected

Phase 3

RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN AMYOTROPHIC LATERAL SCLEROSIS - LIGHTHOUSE II

CompletedCTIS2024-517054-94-00

Stichting TRICALS FoundationAMYOTROPHIC LATERAL SCLEROSIS

Start: 2021-07-05End: 2025-03-26Target: 119Updated: 2024-12-04

A randomised non-inferiority trial with nested PK to assess DTG/3TC fixed dose formulations for the maintenance of virological suppression in children with HIV infection aged 2 to <15 years old

Active, not recruitingCTIS2024-520388-15-00

Fondazione Penta EtsHIV-infected

Start: 2023-06-30Target: 6Updated: 2025-08-12

Phase 4

A multicenter, randomized, controlled, open-label, parallel-group clinical trial in men who have sex with men (MSM) and transgender women with risk sexual behaviors for sexually transmitted infections.

Not yet recruitingCTIS2025-525150-19-01

Instituto De Investigacion Marques De ValdecillaColonization by methicillin-resistant S. aureus and gut microbiota in users of pre-exposure prophylaxis (PrEP) and people living with HIV (PLHIV) with STIs.

Target: 392Updated: 2026-08-06